ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants
Abstract Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that despite a relatively low serum neutralization titre, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (B.1.1.7, P.1, B.1.351 and B.1.617.2) were obtained. The vaccine elicited neutralizing mAbs form 8 distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222 elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post infection. Spike reactive IgG+ B cells were still detectable 9-months post boost. These findings give molecular insights into AZD1222 elicited antibody response..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 09. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seow, Jeffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.09.27.461862 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032700407 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032700407 | ||
| 003 | DE-627 | ||
| 005 | 20231110094040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211001s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.09.27.461862 |2 doi | |
| 035 | |a (DE-627)XBI032700407 | ||
| 035 | |a (biorXiv)10.1101/2021.09.27.461862 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that despite a relatively low serum neutralization titre, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (B.1.1.7, P.1, B.1.351 and B.1.617.2) were obtained. The vaccine elicited neutralizing mAbs form 8 distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222 elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post infection. Spike reactive IgG+ B cells were still detectable 9-months post boost. These findings give molecular insights into AZD1222 elicited antibody response. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Graham, Carl |4 aut | |
| 700 | 1 | |a Hallett, Sadie R. |4 aut | |
| 700 | 1 | |a Lechmere, Thomas |4 aut | |
| 700 | 1 | |a Maguire, Thomas J.A. |4 aut | |
| 700 | 1 | |a Huettner, Isabella |4 aut | |
| 700 | 1 | |a Cox, Daniel |4 aut | |
| 700 | 1 | |a Roberts, Rebekah |4 aut | |
| 700 | 1 | |a Waters, Anele |4 aut | |
| 700 | 1 | |a Ward, Christopher C. |4 aut | |
| 700 | 1 | |a Mant, Christine |4 aut | |
| 700 | 1 | |a Pitcher, Michael J. |4 aut | |
| 700 | 1 | |a Spencer, Jo |4 aut | |
| 700 | 1 | |a Fox, Julie |4 aut | |
| 700 | 1 | |a Malim, Michael H. |4 aut | |
| 700 | 1 | |a Doores, Katie J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 09. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:09 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.celrep.2022.110757 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.09.27.461862 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 09 |c 11 | ||